Pari CKDu Foundation, Tanker Foundation, and Centaur Pharma collaborate to tackle CKDu.2023
Dr. N. Ranganathan, founder of Kibow Biotech and the Pari CKDu Foundation in the United States, has announced a philanthropic partnership with the Tanker Foundation in Chennai and Centaur Pharmaceuticals to investigate novel treatment options for Chronic Kidney Disease of Unknown Etiology (CKDu) patients.
Unlike CKD, which is caused by aging, diabetes, cardiovascular disease, and other medical issues, CKDu patients have no major symptoms.
CKDu affects impoverished farmers and construction workers in India, Sri Lanka, Mesoamerica, and the Balkan States who are exposed to extreme environmental conditions. In contrast to CKD, which is caused by old age, diabetes, cardiovascular disease, and other medical conditions, CKDu patients lack these basic symptoms. It also affects a large number of younger people, typically those in their 30s and 40s.
It is known as CKDu, or CKD of Unknown Origin/Etiology since the illness profile is so different from typical instances of CKD. Heat stress or environmental toxins, such as pesticides, herbicides, and fertilizers, among other plant-based toxins, have long been the subject of discussion among researchers of kidney disease (aristolochic acid, etc.)
The objective of Dr. Ranganathan, the Pari CKDu Foundation, the Tanker Foundation, and Centaur Pharmaceuticals is to investigate the causes and potential remedies for CKDu. To this purpose, preparations have commenced finalizing a protocol for conducting clinical trials, beginning with a pilot-scale investigation of Uddanam Nephropathy.
